前收市價 | 8.80 |
開市 | 8.80 |
買盤 | 7.30 |
賣出價 | 8.70 |
拍板 | 140.00 |
到期日 | 2024-10-18 |
今日波幅 | 8.80 - 8.80 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 20 |
Last week, Ascendis Pharma A/S (NASDAQ:ASND) released topline data on Monday from a trial that included 84 children with achondroplasia, a genetic disorder that causes dwarfism and disproportionate short stature. Goldman Sachs hosted an investor meeting with BioMarin Pharmaceutical Inc's (NASDAQ:BMRN) Alexander Hardy (President and CEO) and Brian Mueller (EVP, CFO). They reiterated financial guidance after reviewing their assumptions around Voxzogo competition post-Ascendis Pharma's better-than-
ASND stock surges after data from a study shows that its investigational achondroplasia therapy achieved the primary study goal.
Ascendis Pharma (ASND) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.